COMMUNIQUÉS West-GlobeNewswire

Vaxcyte Reports Positive Topline Data from Phase 1/2 Study of VAX-31, its 31-Valent Pneumococcal Conjugate Vaccine Candidate, in Adults Aged 50 and Older

03/09/2024 - 13:07

-- At All Doses Studied, VAX-31 Demonstrated Robust Opsonophagocytic Activity Immune Responses for All 31 Serotypes -- -- At Middle and High Doses, VAX-31 Met or Exceeded Regulatory Immunogenicity Criteria for All 31 [...]

GH Research Reports Second Quarter 2024 Financial Results and Provides Business Updates

03/09/2024 - 13:05

Phase 2b clinical trial of GH001 in patients with treatment-resistant depression on track for expected completion of double-blind phase in Q3 2024 and expected completion of 6-month open-label extension phase in Q1 2025 [...]

Amicus Therapeutics to Present at Upcoming Investor Conferences in September 2024

03/09/2024 - 13:05

PRINCETON, N.J., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that management will participate in upcoming presentations at the following investor conferences in September. [...]

Invivyd Announces Continued Neutralizing Activity of PEMGARDA™ (pemivibart) Against Dominant SARS-CoV-2 Variants KP.3.1.1 and LB.1, and Other Variants of Interest

03/09/2024 - 13:01

New pseudovirus in vitro neutralization data show continued neutralizing activity of PEMGARDA™ (pemivibart) against KP.3.1.1, LB.1, and other SARS-CoV-2 variants tested Center for Disease Control reports KP.3.1.1 is the [...]

Fractyl Health to Participate in Upcoming September Investor Conferences

03/09/2024 - 13:00

BURLINGTON, Mass., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (Nasdaq: GUTS) (the “Company”), a metabolic therapeutics company focused on pioneering new approaches that treat root causes of obesity and Type [...]

GH Research Announces Appointment of Dr. Velichka “Villy” Valcheva to Chief Executive Officer

03/09/2024 - 13:00

DUBLIN, Ireland, Sept. 03, 2024 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders, today [...]

Eyenovia Announces Appointment of Experienced Finance and Accounting Executive Andrew Jones as Chief Financial Officer

03/09/2024 - 13:00

Current CFO, John Gandolfo, to remain with the Company through November as part of planned retirement transition NEW YORK, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), a commercial-stage ophthalmic [...]

Bio-Path Holdings to Present at H.C. Wainwright 26th Annual Global Investment Conference

03/09/2024 - 13:00

HOUSTON, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize ® liposomal delivery and antisense technology to develop a portfolio of [...]

PolyPid to Participate in Three Upcoming Fall Investor Conferences

03/09/2024 - 13:00

PETACH TIKVA, Israel, Sept. 03, 2024 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD), (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced that the Company’s [...]

BeyondSpring Announces Oral Presentation at the 2024 World Conference on Lung Cancer and Two Poster Presentations During ESMO Congress 2024 Showcasing its Lead Anti-Cancer Asset, Plinabulin

03/09/2024 - 13:00

FLORHAM PARK, N.J., Sept. 03, 2024 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ: BYSI) (“BeyondSpring” or the “Company”), a clinical-stage global biopharmaceutical company focused on developing innovative cancer [...]

Foghorn Therapeutics Strengthens Leadership Team with Appointment of Anna Rivkin, Ph.D. as Chief Business Officer

03/09/2024 - 13:00

CAMBRIDGE, Mass., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting [...]

Cartesian Therapeutics Announces First Patient Dosed in First-In-Human Phase 1 Trial of Next-Generation mRNA CAR-T Cell Therapy Descartes-15

03/09/2024 - 13:00

Descartes-15 observed to achieve an approximately ten-fold increase relative to Descartes-08 in CAR expression and selective target-specific killing in preclinical studies GAITHERSBURG, Md., Sept. 03, 2024 (GLOBE [...]

Harm Reduction Therapeutics Marks International Overdose Awareness Day With Free Donations of RiVive™ Life-Saving Over-The-Counter Naloxone Nasal Spray

03/09/2024 - 13:00

Donations continue to Remedy Alliance/For The People where it is being distributed to under-resourced harm reduction organizations across the U.S. Additional donations of RiVive™ have been made to Prevention Point [...]

C4 Therapeutics Appoints Veteran Biotechnology Leader Stephen Fawell, Ph.D. to Board of Directors

03/09/2024 - 13:00

WATERTOWN, Mass., Sept. 03, 2024 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today announced [...]

Axogen Reports Inducement Grant to New Employee Under NASDAQ Listing Rule 5635(C)(4)

03/09/2024 - 13:00

ALACHUA, Fla. and TAMPA, Fla., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, announced today [...]

Gain Therapeutics to Participate at H.C. Wainwright 26th Annual Global Investment Conference

03/09/2024 - 13:00

BETHESDA, Md., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of [...]

Oruka Therapeutics Announces Closing of Merger with ARCA biopharma and Previously Announced Private Placement of $275 Million

03/09/2024 - 13:00

Oruka is advancing a pipeline of potentially best-in-class biologics that aim to offer greater freedom from disease to people with plaque psoriasis and other associated conditions Company on track to advance co-lead [...]

Viracta Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference

03/09/2024 - 13:00

SAN DIEGO, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Viracta Therapeutics, Inc. (Nasdaq: VIRX), a clinical-stage precision oncology company focused on the treatment and prevention of virus-associated cancers that impact [...]

Chimerix to Present at H.C. Wainwright 26th Annual Global Investment Conference

03/09/2024 - 13:00

DURHAM, N.C., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ: CMRX), a biopharmaceutical company whose mission it is to develop medicines that meaningfully improve and extend the lives of patients facing deadly [...]